Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expectedto Overexpress αvβ3 and αvβ5 Integrins
Latest Information Update: 24 Jul 2024
At a glance
- Drugs 68Ga-FF58 (Primary)
- Indications Adenocarcinoma; Brain metastases; Glioblastoma; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Diagnostic use; First in man
- Sponsors Novartis Pharmaceuticals
- 18 Jul 2024 Status changed from active, no longer recruiting to discontinued.
- 26 Jun 2024 Planned End Date changed from 26 Jun 2024 to 1 Jul 2024.
- 26 Jun 2024 Planned primary completion date changed from 26 Jun 2024 to 17 Jun 2024.